Just had a quick look at the abstract. Only new info i could find was patient living to 15.5 months. The mention 75% attaining stable disease.
Average lifespan for a GBM patient is less than 12 months. The patients in out trial have already had SOC fail them. So these results are very good.
The 4th Cohort being dosed now are being hit with hopefully the goldilocks amount of cells.
They have a biomarker that the drug is targeting. They have evidence that a carT drug can work against a solid tumour. Noone else has cracked that yet.
Good luck to the 4th cohort.
Ann: CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation, page-14
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |